6 November 2025
Johnson & Johnson's CAPLYTA® Approved by FDA for Major Depressive Disorder Treatment
FDA approves CAPLYTA® as adjunctive therapy for major depressive disorder, showing significant symptom improvement and safety in trials, with potential for remission.